Silver Book Fact

Antihypertensive treatment has generated a benefit-to-cost ratio of at least 6:1 (6:1 in women and 10:1 in men).

Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • “Coronary heart disease spending has increased more than 40% over the past 15 years, and, as a whole, the health improvements have been well worth the costs. Over the entire…  
  • Ischemic stroke patients treated with t-PA (a drug used to treat blood clots) within 3 hours of onset are 33% more likely to be free of disability 3 months after…  
  • Survival Rates of SAS Patients with and without SAVR
    Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
  • Between 1981 and 2004, death rates for heart disease and stroke declined by about 44%.  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…